Grace Therapeutics Nears FDA Decision on GTx-104 for aSAH Treatment

Event summary

  • FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA review.
  • Phase 3 STRIVE-ON trial data presented at Society of Vascular and Interventional Neurology annual meeting in November 2025.
  • Company raised $4.0 million through warrant exercises in October 2025.
  • Q3 2026 net loss reduced to $2.3 million from $4.2 million in Q3 2024.
  • Cash runway extended to at least 12 months from February 2026.

The big picture

Grace Therapeutics is advancing toward a potential FDA approval of GTx-104, a novel treatment for aneurysmal subarachnoid hemorrhage (aSAH), a condition with no meaningful innovation in nearly 40 years. The company's strategic focus on GTx-104, coupled with positive Phase 3 trial results, positions it to capture a significant share of the aSAH market if approved. The upcoming PDUFA date in April 2026 will be a critical inflection point for the company's valuation and commercial prospects.

What we're watching

Regulatory Approval
Whether the FDA will approve GTx-104 by the April 23, 2026 PDUFA date, potentially unlocking a significant market opportunity in aSAH treatment.
Commercial Readiness
The pace at which Grace Therapeutics can build out its commercial team and prepare for a potential GTx-104 launch, given its current cash position.
Pipeline Strategy
How Grace Therapeutics will balance focus on GTx-104 while potentially licensing or selling deprioritized assets like GTx-102 and GTx-101.